New Delhi, Sept. 8 -- Mankind Pharma, a leading pharmaceutical company, announced today that it has received approval from the Central Drugs Standard Control Organisation (CDSCO) to initiate a Phase 1 clinical trial of MKP11093, a novel orally administered Janus kinase-1 (JAK-1) inhibitor.
The molecule is being developed for the treatment of multiple autoimmune disorders, including rheumatoid arthritis, ulcerative colitis, plaque psoriasis, and alopecia, the company said in a statement here.
"Developed at the Mankind Research Centre, MKP11093 has demonstrated strong results in preclinical studies, showing a promising safety and selectivity profile. The molecule targets JAK-1, a key enzyme in the JAK family (JAK1, JAK2, JAK3, TYK2). By inh...